IGM Biosciences, Inc. financial data

Symbol
IGMS on Nasdaq
Industry
Pharmaceutical Preparations
Location
325 E Middlefield Road, Mountain View, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Palingen, Inc. (to 7/16/2010)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 631 % -28.6%
Debt-to-equity 212 % +129%
Return On Equity -191 % -84.8%
Return On Assets -61.1 % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 50.7M USD -61.6%
Weighted Average Number of Shares Outstanding, Basic 60.5M shares +15.7%
Weighted Average Number of Shares Outstanding, Diluted 60.5M shares +15.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 161M USD -25.4%
General and Administrative Expense 50.4M USD +0.67%
Operating Income (Loss) -209M USD +20.8%
Nonoperating Income (Expense) 12.8M USD -27.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -196M USD +20.3%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -196M USD +20.5%
Earnings Per Share, Basic -3.24 USD/shares +31.2%
Earnings Per Share, Diluted -3.24 USD/shares +31.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.5M USD -76.5%
Marketable Securities, Current 236M USD -19.1%
Assets, Current 194M USD -44.3%
Property, Plant and Equipment, Net 32.5M USD -15%
Operating Lease, Right-of-Use Asset 38.5M USD +7.69%
Other Assets, Noncurrent 1.06M USD -41.5%
Assets 266M USD -37.2%
Accounts Payable, Current 983K USD -25.9%
Accrued Liabilities, Current 26.9M USD -14.8%
Liabilities, Current 37.6M USD -11.4%
Operating Lease, Liability, Noncurrent 38.1M USD +9.79%
Other Liabilities, Noncurrent 366K USD
Liabilities 218M USD -1.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 159K USD +5.3%
Retained Earnings (Accumulated Deficit) -1.02B USD -23.8%
Stockholders' Equity Attributable to Parent 48.2M USD -76.3%
Liabilities and Equity 266M USD -37.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42.4M USD +16.8%
Net Cash Provided by (Used in) Financing Activities 152K USD +103%
Net Cash Provided by (Used in) Investing Activities 8.65M USD -87.6%
Common Stock, Shares Authorized 1.2B shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -33.6M USD -278%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.7M USD -76.4%
Deferred Tax Assets, Valuation Allowance 301M USD +12.6%
Deferred Tax Assets, Gross 312M USD +11.7%
Operating Lease, Liability 45.2M USD +11.6%
Depreciation 2.18M USD +30.8%
Payments to Acquire Property, Plant, and Equipment 2.48M USD -36.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -196M USD +20.3%
Lessee, Operating Lease, Liability, to be Paid 56.8M USD +2.91%
Property, Plant and Equipment, Gross 61.8M USD +5.08%
Operating Lease, Liability, Current 7.12M USD +22.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.32M USD +19.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.76M USD -1.69%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.6M USD -5.87%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.52M USD +21.2%
Deferred Tax Assets, Operating Loss Carryforwards 100M USD +36.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 12.6M USD +19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.48M USD +17.4%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%